UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000032512 |
|---|---|
| Receipt number | R000037074 |
| Scientific Title | A search of a new biomaker in the diagnosis of hypertension |
| Date of disclosure of the study information | 2018/05/10 |
| Last modified on | 2021/06/02 08:19:34 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A search of a new biomaker in the diagnosis of hypertension
Acronym
A search of a new biomaker in the diagnosis of hypertension
Scientific Title
A search of a new biomaker in the diagnosis of hypertension
Scientific Title:Acronym
A search of a new biomaker in the diagnosis of hypertension
Region
| Japan |
Condition
Condition
primary aldosteronism
essential hypertension
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
We established whether plasma prorenin levels are available and for the diagnosis of primary aldosteronism.
Basic objectives2
Others
Basic objectives -Others
differentical diagnosis between primary aldosteromism and essential hypertension
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
plasma prorenin
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 90 | years-old | > |
Gender
Male and Female
Key inclusion criteria
the patient with hypertension
the patient (normal contorol) with normtensive in the thyroid disease, such as Graves disease or choronic thyroiditis
Key exclusion criteria
the patient with chornic renal failure
Target sample size
300
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yuji Kamata |
Organization
Kitasato University School of Medicine
Division name
Department of Endocrinology, Diabetes and Metabolism
Zip code
Address
1-15-1 kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan
TEL
042-778-8111
ykamata@med.kitasato-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Yuji Kamata |
Organization
Kitasato University School of Medicine
Division name
Department of Endocrinology, Diabetes and Metabolism
Zip code
Address
1-15-1 kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan
TEL
042-778-8111
Homepage URL
ykamata@med.kitasato-u.ac.jp
Sponsor or person
Institute
Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Kitasato University School of Medicine
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 05 | Month | 10 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 05 | Month | 01 | Day |
Date of IRB
| 2012 | Year | 07 | Month | 03 | Day |
Anticipated trial start date
| 2018 | Year | 06 | Month | 01 | Day |
Last follow-up date
| 2021 | Year | 06 | Month | 02 | Day |
Date of closure to data entry
| 2021 | Year | 06 | Month | 02 | Day |
Date trial data considered complete
| 2021 | Year | 06 | Month | 02 | Day |
Date analysis concluded
Other
Other related information
We established a direct human plasma prorenin in the patinets with hypertension.
Management information
Registered date
| 2018 | Year | 05 | Month | 08 | Day |
Last modified on
| 2021 | Year | 06 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037074
